PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · Real-Time Price · USD
36.66
-0.36 (-0.97%)
At close: Sep 26, 2025, 4:00 PM EDT
36.67
+0.01 (0.03%)
After-hours: Sep 26, 2025, 7:33 PM EDT
PROCEPT BioRobotics Revenue
PROCEPT BioRobotics had revenue of $79.18M in the quarter ending June 30, 2025, with 48.41% growth. This brings the company's revenue in the last twelve months to $274.95M, up 55.71% year-over-year. In the year 2024, PROCEPT BioRobotics had annual revenue of $224.50M with 64.84% growth.
Revenue (ttm)
$274.95M
Revenue Growth
+55.71%
P/S Ratio
7.21
Revenue / Employee
$363,690
Employees
756
Market Cap
2.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 224.50M | 88.31M | 64.84% |
Dec 31, 2023 | 136.19M | 61.18M | 81.55% |
Dec 31, 2022 | 75.01M | 40.54M | 117.60% |
Dec 31, 2021 | 34.47M | 26.76M | 346.72% |
Dec 31, 2020 | 7.72M | 1.55M | 25.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRCT News
- 6 weeks ago - Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy - Seeking Alpha
- 7 weeks ago - PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - GlobeNewsWire
- 2 months ago - PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO - GlobeNewsWire
- 2 months ago - Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy - GlobeNewsWire
- 2 months ago - PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 2 months ago - Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule - GlobeNewsWire
- 4 months ago - 19 stocks at the intersection of AI and robotics that could see big sales boosts - Market Watch